

**Supplementary Table 3.** Two-sample bidirectional Mendelian randomization between VCAN and DKD

| Exposure | Outcome | Method                    | SNPs | Beta   | Standard error | P value | OR (95% CI)         |
|----------|---------|---------------------------|------|--------|----------------|---------|---------------------|
| VCAN     | DKD     | MR Egger                  | 60   | 0.045  | 0.067          | 0.502   | 1.046 (0.176–0.918) |
|          |         | Weighted median           | 60   | 0.084  | 0.049          | 0.085   | 1.087 (0.179–0.989) |
|          |         | Inverse variance weighted | 60   | 0.084  | 0.034          | 0.014   | 1.088 (0.151–1.017) |
|          |         | Simple mode               | 60   | 0.096  | 0.095          | 0.313   | 1.101 (0.281–0.915) |
|          |         | Weighted mode             | 60   | 0.090  | 0.070          | 0.200   | 1.095 (0.227–0.955) |
| DKD      | VCAN    | MR Egger                  | 98   | 0.020  | 0.024          | 0.412   |                     |
|          |         | Weighted median           | 98   | –0.001 | 0.026          | 0.960   |                     |
|          |         | Inverse variance weighted | 98   | 0.015  | 0.016          | 0.338   |                     |
|          |         | Simple mode               | 98   | 0.008  | 0.054          | 0.884   |                     |
|          |         | Weighted mode             | 98   | 0.001  | 0.025          | 0.983   |                     |

VCAN, versican; DKD, diabetic kidney disease; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.